AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05125159 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture
Description: Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
Study NCT05125159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture
Description: Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
Study NCT05994612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention
Description: 10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
Study NCT05994612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Participants will receive services that they would normally receive in the community.
Study NCT05994612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Participants will receive services that they would normally receive in the community.
Study NCT06406712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular block
Description: regional anesthesia
Study NCT06366607 — intervention group
Intervention type: OTHER
Intervention: high-alert medication administration
Description: high-alert medication administration
Study NCT05413668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVP-001
Description: Intravenous administration of RVP-001
Study NCT05413668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of saline placebo
Study NCT01007903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: 12-week tai chi exercise class
Study NCT04826172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: Modified release (MR) oral tablet
Study NCT04826172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet
Study NCT04107662 — intervention group
Intervention type: DEVICE
Intervention: Tbit system
Description: Suspected traumatic brain injury with head CT
Study NCT04789707 — intervention group
Intervention type: BEHAVIORAL
Intervention: auto-questionnaire
Description: Patients answer the auto questionnaire in last minutes of consultation.
Study NCT05399069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGR-R01
Description: Gene Replacement Therapy
Study NCT05962866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I and II. Performing Leopold Maneuvers by the pregnant
Description: 24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
Study NCT05822557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus Pouch Feed
Description: Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
Study NCT06243198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered subcutaneously (SC)
Study NCT06243198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (SC)
Study NCT05794425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 3-5 mg per kilogram per day.
Study NCT05794425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood & Umbilical cord derived mesenchymal stem cells
Description: Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
Study NCT05842317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Plus Tislelizumab
Description: Lenvatinib is 12mg/d for body weight >= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
Study NCT05842317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization(TACE)
Description: A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
Study NCT06452537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
Study NCT06452537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
Study NCT03920111 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IMOJEV
Description: live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
Study NCT04892641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Epetraborole hydrochloride 250 mg tablets for oral administration
Study NCT04892641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
Study NCT05980806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Description: Participants will receive selinexor 60 mg oral tablets QW.
Study NCT05980806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg
Description: Participants will receive selinexor 40 mg oral tablets QW.
Study NCT05980806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
Study NCT05980806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will receive pacritinib 200 mg twice daily.
Study NCT03971630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients will be followed up using the MyVENT System and APP
Study NCT05980806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Participants will receive momelotinib 200 mg once daily.
Study NCT06415890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 Breathing Technique
Description: The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
Study NCT05668234 — intervention group
Intervention type: OTHER
Intervention: interview
Description: semi-directive interview
Study NCT05441241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller
Description: The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
Study NCT05441241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional distraction techniques
Description: Common distraction techniques will be used (i.e., visual stimulation, lecture)
Study NCT01645293 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetically modified T cells # 1138
Study NCT05665439 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
Study NCT05261386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-008
Description: Treat MGD
Study NCT05261386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBT-008
Description: Treat MGD
Study NCT06347198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
Study NCT06347198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
Study NCT06347198 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sintilimab
Description: Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
Study NCT06347198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
Study NCT06347198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
Study NCT06571305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study NCT06571305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS)
Description: MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study NCT05618522 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vacuum-dehydrated amnion membrane (omnigen)
Description: applying the lens loaded with Omnigen on the cornea
Study NCT05618522 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: the lens loaded with Omnigen
Description: the lens loaded with Omnigen
Study NCT05603117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)
Description: CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
Study NCT06495372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimenta group (standard of care + Methoxyflurane).
Description: standard of care + Methoxyflurane
Study NCT06495372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group (standard of care + placebo).
Description: standard of care + placebo
Study NCT05803655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 36-hour duration between ovulation triggering and oocyte pick-up procedure
Description: 36-hour duration between ovulation triggering and oocyte pick-up procedure
Study NCT05803655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 38-hour duration between ovulation triggering and oocyte pick-up procedure
Description: 38-hour duration between ovulation triggering and oocyte pick-up procedure
Study NCT04980534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid and Asbrip
Description: Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
Study NCT04980534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Standard Therapy
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Study NCT04980534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Standard Therapy
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Study NCT04923477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome
Description: Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
Study NCT04689659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell treatment
Description: CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
Study NCT05939531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOUNCE Program
Description: Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
Study NCT05939531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard post-stroke care
Study NCT05990387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Dose-response effect on thermogenesis
Study NCT05601687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Endoscopic Necrosectomy
Description: Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
Study NCT05601687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up Approach
Description: Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON.
Study NCT05990387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control condition
Study NCT04565626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional weekend physiotherapy
Description: Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
Study NCT05981625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Giomer varnish containing surface pre-reacted glass fillers
Description: Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity
Study NCT05981625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer varnish containing surface pre-reacted glass fillers
Description: Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity
Study NCT05728320 — intervention group
Intervention type: DEVICE
Intervention: Glucose monitoring with flash glucose monitor
Description: All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.
Study NCT06291948 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira® (adalimumab) AC Pen [Reference Product]
Description: A single subcutaneous dose
Study NCT06291948 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Richmond [Test Product]
Description: A single subcutaneous dose
Study NCT04556721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
Study NCT06446921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger formula
Description: supplement delivering a minimum of 20 mg of gingeroids / d
Study NCT06446921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: arabic gum
Study NCT05049590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Description: A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
Study NCT05235126 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Decoria intense
Description: All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).